Alanza

Alanza is a biotechnology company focused on developing next-generation delivery technologies for nucleic acid therapeutics, such as siRNA and mRNA. Founded by David Lewis, a pioneer in the RNAi field and former CSO of Arrowhead Pharmaceuticals, the company leverages deep expertise in polymer chemistry to solve the delivery problem in genetic medicine. Alanza's platform is designed to enable the precise and efficient transport of therapeutic payloads to diverse tissues beyond the liver. The company's goal is to broaden the clinical utility of RNA-based drugs across a range of high-need therapeutic areas, including oncology and rare genetic disorders. By optimizing the chemical properties of delivery vehicles, Alanza aims to improve the safety and efficacy profiles of genetic medicines.